

Journal of Medical Sciences

ISSN 1682-4474





Research Paper

J. Med. Sci., 5 (4): 289-293 October-December, 2005

JMS (ISSN 1682-4474) is an International, peer-reviewed scientific journal that publishes original articles in experimental & clinical medicine and related disciplines such as molecular biology, biochemistry, genetics, biophysics, bio-and medical technology. JMS is issued four times per year on paper and in electronic format.

For further information about this article or if you need reprints, please contact:

Noreen Samad C/O Prof. Dr. Darakhshan Jabeen Haleem Department of Biochemistry University of Karachi Karachi-75270, Pakistan

Attenuation of Restraint-induced Anorexia and Anxiogenic Behavior by Serotonin-1A Agonists in Rats

Noreen Samad, Tahira Parveen, Saida Haider and Darakhshan Jabeen Haleem

The present study was designed to investigate the effects of buspirone (a partial 5-HT 1A receptor agonist) and 8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT, a full 5-HT 1A receptor agonist) on restraint-induced behavioral deficits. Exposure to a single episode of 2 h restraint stress decreased food intake, growth rate and elicited anxiogenic like behavior in rats. Prior administration of buspirone and 8-OH-DPAT attenuated stress-induced behavioral deficits of food intake and exploratory activity in a light-dark box. Novelty-induced anxiety in unrestrained animals was also diminished by prior administration of 8-OH-DPAT but not buspirone. The effects on the attenuation of restraint-induced anorexia were greater in 8-OH-DPAT than buspirone injected animals. The results are discussed in the context of a role of somatodendritic as well as postsynaptic 5-HT 1A receptors in the attenuation of restraint-induced behavioral deficits.

Key words: Stress, somatodendritic 5-HT 1A receptor, postsynaptic 5-HT 1A receptor, 8-OH-DPAT, buspirone



Department of Biochemistry, Neurochemistry and Biochemical Neuropharmacology Research Unit, University of Karachi, Karachi-75270, Pakistan

INTRODUCTION

Rats exposed to 2 h restraint-stress exhibited decreased locomotion together with decreased food intake and growth rate^[1,2]. On repeated immobilization these behavioral deficits were no longer observed^[3,4]. A variety of stress stimuli increase the synthesis and turnover of 5-hydroxytryptamine (5-HT, serotonin) in whole brain and various brain region of rats^[1,5-7]. When repeatedly restrained behaviorally adapted rats were challenged with an episode of 2 h restraint 5-HT synthesis did not increase in various brain regions[8]. In view of 5-HT hypothesis of depression, an increase in 5-HT function would be expected to produce adaptation to stress[8]. It was therefore argued that change in sensitivity of serotonin receptors is involved in adaptation to stress. Later study showed that following adaptation to stress the sensitivity of 5-HT 1A autoreceptors located on the cell soma and/or dendrites of serotonergic neurons is decreased^[4] when these receptors are desensitized, their response would become less effective to increase synaptic availability of 5-HT^[9]. Greater serotonin function may therefore lead to adaptation to stress.

Buspirone, a partial 5-HT 1A agonist^[10] stimulates somatodendritic 5-HT 1A receptor and 8-OH-DPAT, a full 5-HT 1A agonist^[11] acts via both somatodendritic as well as postsynaptic 5-HT 1A receptors. These drugs have been shown to elicit antianxiety^[12] and antidepressant-like^[13] effects in various animal models.

To get an insight in to the role of somatodendritic and/or postsynaptic 5-HT 1A receptors the present study concerns the effect of buspirone and 8-OH-DPAT on restraint-induced behavioral deficits in rats.

MATERIALS AND METHODS

Animals and treatment: Thirty-six locally bred male albino Wistar rats weighing 230-275 g were housed individually in plastic cages with free access to cubes of standard rodent diet and tap water.

Experimental protocol: The animals divided into saline, buspirone and propranolol injected groups. Buspirone was injected at a dose of (0.2 mg kg⁻¹) for 3 days^[14], while 8-OH-DPAT was injected at a dose of (0.25 mg kg⁻¹) for 3 days^[15]. Control animals were injected with saline in volume of (1 mL kg⁻¹). Food intake and body weights were monitored during the treatment. After 3 days of drug administration animals of each group were further divided into unrestrained and restrained groups. Animals of restrained group were immobilized for 2 h (11:00 and 13:00 h). Animals of unrestrained group were left in their home cages during this time. Effects of restraint stress on

24 h cumulative food intake, body weight changes and exploratory activity in a light-dark box (for 5 min) were monitored next day.

Restraining the animals: The animals were restrained on wire grids of 10"x9" fitted with a Perspex plate of 9"x6.5". Restraining procedure was same as described earlier^[3]. Immobilization was affected by pressing the fore legs of the rats through the gaps in the metal grids and taping them together with Zinc Oxide plaster tape. Hind limbs were also taped and the head of animal rested on the Perspex plate. After 2 h of restraining period the animals were released and returned to their home cage.

Light-dark activity test: Exploratory activity in a light-dark box was monitored 24 h after the termination of 2 h restraint period. A rat placed in this box is expected to pass more time spent in the dark compartment. To determine the activity, a rat was placed in the light-dark compartment of the box. Time spent in the light compartment was monitored for a cut off time of 5 min.

Statistical analysis: Data were analyzed by Two-way ANOVA. Post-hoc analysis was done by Newman-Keuls test: p values < 0.05 were taken as significant.

RESULTS

Two-way ANOVA performed on 24 h cumulative food intake in saline, buspirone and 8-OH-DPAT treated animals (Table 1) showed that effect of drug (F = 12.06, df = 2.30, p<0.01), stress (F = 144.51, df = 1.30, p<0.01) and interaction between stress and drugs (F = 5.64, df = 1.30, p<0.05) were significant. Post-hoc analysis by Newman-Keuls test showed that 2 h restraint decreased 24 h cumulative food intake in saline as well as buspirone and 8-OH-DPAT treated animals. The decreases were smaller in buspirone and 8-OH-DPAT treated than saline treated animals. 24 h cumulative food intakes were greater in 8-OH-DPAT than buspirone injected restrained animals.

Two-way ANOVA performed on 24 h changes of growth rate in saline, buspirone and 8-OH-DPAT treated animals (Table 2) showed significant effect of drugs (F = 6.95, df = 2,30, p<0.05), stress (F = 85.1, df = 1,30, p<0.01) and significant interaction between the two factors (F = 6.37, df = 1,30, p<0.05). Post-hoc analysis showed that an episode of 2 h restraint stress decreased growth rate in saline as well as in buspirone and 8-OH-DPAT injected animals. Growth rates of saline, buspirone and 8-OH-DPAT injected unrestrained animals exhibited higher growth rate than saline and buspirone injected unrestrained animals.

Table 1: Effect of 2 h restraint stress on 24 h cumulative food intake in saline busnirone and 8-OH-DPAT treated animals

samie, caspilone and s our built a case a aminan			
Injections	Unrestrained	Restrained	
Saline (1 mL kg ⁻¹)	14.4±3.7	$2.2\pm1.8^{*}$	
Buspirone (0.2 mg kg ⁻¹)	15.8±2.5	5.7±1.1*,+	
8-OH-DPAT (0.25 mg kg ⁻¹)	16.7±2.4	8.4±2.5*,++	

Values are means±SD (n = 6). Significant differences by Newman-Keuls test, *p<0.01 from respective unrestrained animals, *p<0.05, **p<0.01 from respective restrained rats following Two-way ANOVA

Table 2: Effect of 2 h restraint stress on 24 h changes of growth rate in saline, buspirone and 8-OH-DPAT treated animals

Injections	Unrestrained	Restrained
Saline (1 mL kg ⁻¹)	100.0±1.0	96.0±1.2*
Buspirone (0.2 mg kg ⁻¹)	100.1 ± 0.5	$97.2\pm0.9^*$
8-OH-DPAT (0.25 mg kg ⁻¹)	101.9±1.8 ^{+,#}	97.0±1.6*

Values are means \pm SD (n = 6). Significant differences by Newman-Keuls test, *p<0.01 from respective unrestrained, *p<0.01 from saline injected unrestrained rats, *p<0.01 from buspirone treated unrestrained animals following Two-way ANOVA

Table 3: Effect of 2 h restraint stress on time spent in light dark compartment of a light dark box in rats treated with saline, buspirone and 8-OH-DPAT

Injections	Unrestrained	Restrained
Saline (1 mL kg ⁻¹)	80.0±9.8	52.3±7.2*
Buspirone (0.2 mg kg ⁻¹)	88.8±16.3	78.6±15.0+
8-OH-DPAT (0.25 mg kg ⁻¹)	160.8±12.6 ^{+,#}	124.8±9.02*,+,#

Values are means \pm SD (n = 6) 24 h after the termination of stress. Significant differences by Newman-Keuls test, *p<0.01 from respective unrestrained animals, *p<0.01 from respective saline treated animals, *p<0.01 from respective buspirone injected animals following Two-way ANOVA

Two-way ANOVA performed on time spent in light box (light-dark activity) in saline, buspirone and 8-OH-DPAT treated animals (Table 3) showed significant effect of drugs (F = 120.21, df = 2.30, p<0.01), stress (F = 37.18, df = 1.30, p<0.01) and stress*drug (F = 149.32, df = 1.30, p<0.01). Post-hoc analysis showed that an episode of 2 h restraint stress decreased time spent in light compartment in saline and 8-OH-DPAT treated animals but not in buspirone treated animals. Buspirone and 8-OH-DPAT injected restrained animals spent greater time in light compartment than saline treated restrained animals. Values in 8-OH-DPAT injected unrestrained as well as restrained animals were greater than the respective values in saline or buspirone treated animals.

DISCUSSION

The effect of 2 h restraint stress on food intake (Table 1), growth rate (Table 2) and exploratory activity in a lit compartment (Table 3) largely agreed with previous data^[3,16,17]. Shiamada *et al.*^[18] reported that exposing rats to a stress inducing situation decreases exploration of light compartment in a light-dark activity box. In addition, the present study shows that administration of 8-OH-DPAT as well as buspirone attenuated restraint- induced deficits of lit box exploration. An increase in time spent in light compartment is used as a measure of anxiolytic profile of a drug^[17,18].

8-OH-DPAT and buspirone have been shown to produce anxiolytic effect in various models of anxiety^[19,20]. There is substantial evidence for a key role of 5-HT 1A autoreceptors in mediating the anxiolytic effect of buspirone and 8-OH-DPAT^[21], in addition, several studies have provided a supporting role of postsynpatic 5-HT 1A receptors in the anxiolytic-like action of buspirone and other 5-HT 1A agonist^[22,23].

In the present study 8-OH-DPAT injected but not buspirone injected unrestrained animals also exhibited greater time spent in light box (Table 3). The results suggest that a full but not partial 5-HT 1A agonist could decrease novelty-induced anxiety.

Buspirone is a partial agonist at 5-HT 1A postsynaptic receptor, but a full agonist at 5-HT 1A presynaptic somatodendritic receptors^[24]. It inhibits 5- HT cell firing^[25] and thereby reduced 5-HT neurotransmission^[26]. Acute administration of buspirone at doses from (1-20 mg kg⁻¹) has been shown to decrease synthesis and release of 5-HT by stimulation of somatodendritic 5-HT 1A receptors^[27]. It also reduced extracellular levels of 5-HT in the hippocampus^[28].

8-OH-DPAT a full agonist at 5-HT 1A receptors stimulate postsynaptic receptor to produce hyperactivity syndrome^[29] and presynaptic receptors to decrease 5-HT turnover, synthesis and release by a feedback mechanism^[30,31]. 8-OH-DPAT at a dose 60 µg kg⁻¹ sufficient to activate cell body but not postsynaptic 5-HT metabolism in the hippocampus^[32]. Acute stimulation of somatodendritic 5-HT 1A receptor by 8-OH-DPAT decreased 5-HT metabolism and synthesis rate^[33,34]. Sprouse and Aghajanian^[25] have reported that activation of the somatodendritic 5-HT 1A receptor which are pre-dominantly located in the dorsal raphe nucleus result in an inhibition of the firing of 5-HT neuron. Consequently, leading to a decrease in 5-HT neurotransmission in their forebrain projection area^[35].

Regarding the anxiolytic effect after microinjection of 5-HT 1A agonist in brain region located postsynaptically to the serotonergic neurons. The stimulation of postsynaptic 5-HT 1A receptors might trigger a neuronal feedback loop terminating in the dorsal raphe nuclei, where it might exert an inhibitory influence on serotonergic neurons^[36,37].

The resultant decrease in 5-HT levels is thought to be involved in the anxiolytic effect of postsynaptic 5-HT 1A receptor stimulation.

The present study shows that stimulation of pre as well as postsynaptic 5-HT 1A receptors by buspirone and 8-OH-DPAT could attenuate restraint-induced behavioral deficits. Attenuation of novelty-induced anxiety by 8-OH-DPAT but not buspirone in unrestrained

animals is largely explicable in term of a feedback effect exerted on dorsal raphe neuronal firing by postsynaptic 5-HT 1A receptors. The finding may have implication in the treatment of stress-related disorders such as depression and anxiety.

REFERENCES

- Haleem, D.J., G.A. Kennet and G. Curzon, 1988. Adaptation of female rats to stress: Shift to male pattern by inhibition of corticosterone synthesis. Brain Res., 458: 339-47.
- Samad, N., T. Parveen, S. Haider and D.J. Haleem, 2002. Effect of repeated injection of neem leaf extract and restraint stress on a model of anxiety and brain serotonin metabolism in rats. J. Hamdard Medicus, 45: 54-58.
- Haleem, D.J. and T. Parveen, 1994. Effect of restraint on brain regional 5-HT synthesis rate following adaptation to repeated restraint. NeuroReport, 5: 1785-1788.
- Haleem, D.J. 1999. Serotonergic mechanism of antidepressant action and adaptation to stress.
 J. College Physician and Surgeon Pak., (JCPSP) 9: 139-46.
- Curzon, G., M.H. Joseph and P.J. Knott, 1972. Effect of immobilization and food deprivation on rat brain serotonin metabolism. J. Neurochem., 19: 1967-1974.
- Kennett, G., M.H. Joseph, 1981. The functional importance of increased brain tryptophan in the serotonergic response to restraint stress. Neuropharmacology, 20: 39-43.
- Chauoloff, F., D. Joseph and J.L. Elghozi, 1989. Physical exercise: Evidence for differential consequence of tryptophan on 5-HT synthesis and metabolism in central serotonergic cell bodies and terminals. J. Neuronal Transm., 78: 121-130.
- Kennett, G.A., T. Dourish and G. Curzon, 1987. Antidepressant-like action of 5-HT 1A agonist and conventional antidepressant in an animal model of depression. Eur. J. Pharamacol., 134: 265-274.
- Haleem, D.J., Z.S. Saify, S. Siddiqui, F. Batool and M.A. Haleem, 2002. Pre and postsynaptic receptors to 1-(1-napthyl piperazine) following adaptation to stress in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 26: 149-56.
- Johnson, B.A., 2004. Role of the serotonergic system in the neurobiology of alcoholism: Implications for treatment. CNS Drugs, 18: 1105-1118.

- Collinson, R. and G.R. Dawson, 1997. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology, 132: 35-43.
- Sivarao, D.V., K. Newberry and N.J. Lodge, 2004.
 Effect of the 5HT1A receptor partial agonist buspirone on colorectal distension-induced pseudoaffective and behavioral responses in the female Wistar rat. Eur. J. Pharmacol., 494: 23-29.
- 13. Harvey, K.V. and R. Balon, 1995. Augmentation with buspirone: A review. Ann. Clin. Psychiatry, 7: 143-147.
- 14. Ossowska, G., W. Zebrowska-Lupina, Z. Danikzuk and B. Klenk-Majewska, 2002. Repeated treatment with selective serotonin reuptake inhibitors but not anxiolytics prevents the stress-induced deficits of fighting behaviour. Pol. J. Pharmacol., 54: 373-380.
- Lopez-Rubalcova, C. and Fernandez-Guastin, 1994.
 Noradrenaline-serotonin interaction in the anxiolytic effect of 5-HT 1A agonists. Behav. Pharamacol., 5: 42-51.
- Haleem, D.J., 1996. Adaptation to repeated restraint in rats: Failure of ethanol treated rats to adapt in the stress schedule. Alcohol and Alcoholism, 31: 471-477.
- Samad, N., T. Parveen, S. Haider and D.J. Haleem, 2004. Buspiorne and propranolol attenuate restraint induced behavioral deficits in rats. J. College Physician and Surgeon Pak., (JCPSP) [In Press].
- Shamada, T., K. Mtsumoto, M. Osanai, H. Matsuda, K. Terasawa and H. Watanabe, 1995. The modified light/dark transition test in mice: Evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen. Pharamacol., 26: 205-210.
- Netto Mendonca, S. and F.S. Guimaraes, 1996. Role of hippocampal 5-HT 1A receptors on elevated plus maze exploration after a single restraint experience. Behav. Brain Res., 77: 215-218.
- File E.S., E.L. Gonzalez and A. Nick, 1996. Comparative study of pre and postsynaptic 5-HT 1A receptor modulation of anxiety in two ethological animals test. J. Neurosci., 16: 4810-4815.
- 21. De Vry, J., 1995 5-HT 1A receptor agonists: Recent developments and controversial issues. Psychopharmacology, 121: 1-26.
- Kostowski, W., A. Planzik and R. Sterfanski, 1989. Intra-hippocampal buspirone in animals models of anxiety. Eur. J. Pharmacol., 198: 393-396.

- Stefanski, R., W. Palejko, A. Bidzinski, W. Kostowski and A. Plaznik, 1993. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT 1A receptor agonists. Neuropharamacology, 32: 977-985.
- Hjorth, S. and A. Carlsson, 1982. Buspirone effects on central monoaminergic transmissionpossible relevance to animals experimental and clinical findings. Eur. J. Pharamacol., 83: 299-303.
- Sprouse, J.S. and G.K. Aghajanian, 1987.
 Electrophysiological responses of serotonergic dorsal raphe neurons to 5-HT 1A and 5-HT 1B agonists. Synapse, 1: 3-9.
- Hamon, M., C.M. Fattaccini, J. Adrien, M.C. Gallissol, P. Martin and H. Gozlan, 1988. Alteration of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine 1A agonist with potential anxiolytic properties. J. Pharamacol.Exp.Ther., 246: 745-752.
- VanderMealen, C.P., G.K. Matheson, R.C. Wildman and L.A. Patterson, 1986. Inhibition of serotonergic dorsal raphe neurons by systemic and ionophoretic administration of buspirone, a non-benzadiazepine anxiolytic drug. Eur. J. Pharamacol., 129: 123-30.
- Liu, Y.P., L.S. Wilkinson and T.W. Robbinson, 2004. Effect of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex. Psychopharmacology, 173: 175-185.
- 29. Haleem, D.J. 1992. Sex differences in neurochemical and behavioral effects of 8-hydroxy-2-(di-n-propylamino) tetraline. Life Sci., 50: 221-226.
- Huston, P.M., G.S. Sarna, M.T. O'Connell and G. Curzon, 1989. Hippocampal 5-HT synthesis and release *in vivo* is decrease by infusion of 8-OH-DPAT into the nucleus raphe dorsalis. Neurosci. Lett., 100: 276-280.

- Haleem, D.J., G.A. Kennett and G. Curzon, 1990.
 Hippocampal 5-HT synthesis is greater in female than male rats and is more decrease by 5-HT 1A agonist 8-OH-DPAT. J. Neuronal. Transm., 79: 93-101.
- Huston, P.H., C.I. Dourish and G. Curzon, 1986. Neurochemical and behavioral evidence for mediation of hyperphagic action of 8-OH-DPAT by cell body autoreceptors. Eur. J. Pharmacol., 129: 347-352.
- 33. Hjorth, S., A. Carlsson, P. Lindber, D. Sarchoz, H. Wikstrom, L.E. Arvidsson, U. Hacksell and J.L.G. Nilsson, 1982. 8-hydroxy-2-(di-n-propylamino) tetraline (8-OH-DPAT), a potent and selective simplified ergot congener with central 5-HT receptor stimulating activity. J. Neural. Transm., 55: 169-88.
- Sharp, T., S.R. Bramwell. and D.G. Grahame-Smith, 1989. 5-HT 1 agonist reduces 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharamcol., 96: 283-90.
- Sharp, T. and S. Hjorth, 1990. Application of brain microdialysis to study the pharmacology of the 5-HT 1A autoreceptor. J. Neurosci. Methods, 34: 83-90.
- 36. Blier, P. and C. De Montigny, 1987. Modification of 5-HT neuron properties by substantiated administration of the 5-HT 1A agonist gepirone: Electrophysiological studies in the rat brain. Synapse, 1: 470-480.
- Ceci, A., A. Baschirotto and I. Borsini, 1994. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotonergic neurons in rats is attenuated by lesions of the frontal cortex. Neuropharmacology, 33: 709-713.